181 related articles for article (PubMed ID: 27224908)
1. Methodological Issues in Conducting Pilot Trials in Chronic Pain as Randomized, Double-blind, Placebo-controlled Studies.
Tominaga Y; Koga H; Uchida N; Wanibe M; Hirose K; Matsumura T; Okamoto A; Richarz U; Etropolski M
Drug Res (Stuttg); 2016 Jul; 66(7):363-70. PubMed ID: 27224908
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.
Schwartz S; Etropolski M; Shapiro DY; Okamoto A; Lange R; Haeussler J; Rauschkolb C
Curr Med Res Opin; 2011 Jan; 27(1):151-62. PubMed ID: 21162697
[TBL] [Abstract][Full Text] [Related]
3. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy.
Vinik AI; Shapiro DY; Rauschkolb C; Lange B; Karcher K; Pennett D; Etropolski MS
Diabetes Care; 2014 Aug; 37(8):2302-9. PubMed ID: 24848284
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
Afilalo M; Morlion B
Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
[TBL] [Abstract][Full Text] [Related]
5. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
[TBL] [Abstract][Full Text] [Related]
6. A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain.
Etropolski M; Lange B; Goldberg J; Steup A; Rauschkolb C
J Opioid Manag; 2013; 9(5):343-56. PubMed ID: 24353047
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
Afilalo M; Etropolski MS; Kuperwasser B; Kelly K; Okamoto A; Van Hove I; Steup A; Lange B; Rauschkolb C; Haeussler J
Clin Drug Investig; 2010; 30(8):489-505. PubMed ID: 20586515
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
Buynak R; Shapiro DY; Okamoto A; Van Hove I; Rauschkolb C; Steup A; Lange B; Lange C; Etropolski M
Expert Opin Pharmacother; 2010 Aug; 11(11):1787-804. PubMed ID: 20578811
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials.
Etropolski M; Kuperwasser B; Flügel M; Häufel T; Lange B; Rauschkolb C; Laschewski F
Adv Ther; 2014 Jun; 31(6):604-20. PubMed ID: 24985410
[TBL] [Abstract][Full Text] [Related]
10. A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy.
Schwartz S; Etropolski MS; Shapiro DY; Rauschkolb C; Vinik AI; Lange B; Cooper K; Van Hove I; Haeussler J
Clin Drug Investig; 2015 Feb; 35(2):95-108. PubMed ID: 25503082
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies.
Lange B; von Zabern D; Elling C; Dubois C
Curr Med Res Opin; 2017 Aug; 33(8):1413-1422. PubMed ID: 28537506
[TBL] [Abstract][Full Text] [Related]
12. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain.
Biondi DM; Xiang J; Etropolski M; Moskovitz B
J Opioid Manag; 2015; 11(5):393-403. PubMed ID: 26535967
[TBL] [Abstract][Full Text] [Related]
13. Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study.
Serrie A; Lange B; Steup A
Curr Med Res Opin; 2017 Aug; 33(8):1423-1432. PubMed ID: 28537501
[TBL] [Abstract][Full Text] [Related]
14. Dose conversion between tapentadol immediate and extended release for low back pain.
Etropolski MS; Okamoto A; Shapiro DY; Rauschkolb C
Pain Physician; 2010; 13(1):61-70. PubMed ID: 20119464
[TBL] [Abstract][Full Text] [Related]
15. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy.
Niesters M; Proto PL; Aarts L; Sarton EY; Drewes AM; Dahan A
Br J Anaesth; 2014 Jul; 113(1):148-56. PubMed ID: 24713310
[TBL] [Abstract][Full Text] [Related]
16. Tapentadol extended release for chronic pain patients.
Taylor R; Pergolizzi JV; Raffa RB
Adv Ther; 2013 Jan; 30(1):14-27. PubMed ID: 23328938
[TBL] [Abstract][Full Text] [Related]
17. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study.
Uberall MA; Mueller-Schwefe GH; Terhaag B
Curr Med Res Opin; 2012 Oct; 28(10):1617-34. PubMed ID: 22970658
[TBL] [Abstract][Full Text] [Related]
20. Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.
Buynak R; Rappaport SA; Rod K; Arsenault P; Heisig F; Rauschkolb C; Etropolski M
Clin Ther; 2015 Nov; 37(11):2420-38. PubMed ID: 26428249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]